NVAX
NOVAVAX INC
Key Financials
Net Income
$440.3M
↑ 334.8%
Operating Income
$452.8M
↑ 281.9%
Total Assets
$1.2B
↓ 24.6%
EPS (Diluted)
$2.58
↑ 309.8%
Total Liabilities
$1.3B
↓ 40.3%
Cash & Equivalents
$240.6M
↓ 54.6%
Shareholders' Equity
$-127753000.00
↑ 79.5%
Long-term Debt
$291.0M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 4 | 6/23/2026 | View on SEC |
| 8-K | 6/23/2026 | View on SEC |
| 144 | 5/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NVAX |
| Company Name | NOVAVAX INC |
| CIK | 1000694 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-268-2000 |